索拉非尼对一名肾转移性集合管癌患者诱导出治疗反应。
Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
作者信息
Ansari Jawaher, Fatima Arfeen, Chaudhri Shalini, Bhatt Rupesh I, Wallace Michael, James Nicholas D
机构信息
University Hospital Birmingham NHS Trust, Queen Elizabeth Hospital, Metchley Drive, Birmingham, UK.
出版信息
Onkologie. 2009 Feb;32(1-2):44-6. doi: 10.1159/000183736. Epub 2009 Jan 19.
BACKGROUND
Collecting duct carcinoma (CDC) is a rare and aggressive variant of renal cell carcinoma (RCC), which has poor response to cytokine therapy and chemotherapy. Introduction of tyrosine kinase inhibitors (TKIs), in particular sorafenib and sunitinib, is changing the treatment paradigm for management of RCC. However, patients with CDC have been excluded from the majority of randomised trials involving the use of TKIs.
CASE REPORT
Our patient with metastatic CDC was treated with sorafenib, and demonstrated an excellent response, both clinically and radiologically. She continues on sorafenib treatment with minimal toxicity, and has demonstrated a progression-free survival exceeding 13 months.
CONCLUSIONS
This is the first reported case of a patient with CDC responding to sorafenib treatment. Therefore, the role of sorafenib in the management of metastatic CDC needs prospective evaluation.
背景
集合管癌（CDC）是肾细胞癌（RCC）中一种罕见且侵袭性强的亚型，对细胞因子治疗和化疗反应不佳。酪氨酸激酶抑制剂（TKIs）的引入，尤其是索拉非尼和舒尼替尼，正在改变RCC的治疗模式。然而，大多数涉及使用TKIs的随机试验都将CDC患者排除在外。
病例报告
我们的转移性CDC患者接受了索拉非尼治疗，在临床和影像学上均显示出极佳的反应。她继续接受索拉非尼治疗，毒性极小，无进展生存期已超过13个月。
结论
这是首例报告的CDC患者对索拉非尼治疗有反应的病例。因此，索拉非尼在转移性CDC治疗中的作用需要进行前瞻性评估。
Zotero 插件